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Abstract: Indonesia has implemented multiple strategies to control Highly Pathogenic Avian Influenza H5N1 (HPAI/H5N1), including the licensure and use of multiple vaccine formulations. The continuous drift of Indonesian HPAI/H5N1 viruses and emergence of a new clade in 2012 that became dominant in 2016, demands the assessment of commercial vaccine formulations against Indonesian field viruses. Seven databases were explored to identify relevant literature reporting the performance of commercial vaccines against Indonesian HPAI/H5N1 viruses. After methodological assessment, data were collated and analyzed to report immunogenicity and vaccine efficacy (VE) to prevent respiratory and cloacal viral shedding 2-day post challenge, and death at the end of the follow-up period. Meta-analyses were performed to assess VE consistency of alternative formulations and to explore potential sources of heterogeneity in VE. In total, 65 studies and 46 vaccine formulations from 13 articles were grouped per OIE's VE protocols (group 1) and variations of it (groups 2,3,4). We found that antigenic closeness between vaccine-seed and challenge virus might be a better proxy of VE than current estimates based on vaccine-homologous HI antibody titers, particularly against current fourth order clade viruses (groups 1&2). Prime-boosting was efficacious across different chicken breeds (group 3), and early vaccination may increase the risk of death (group 4). One Indonesian vaccine was tested against the new dominant clade, conferring consistent protection in chickens but not in ducks. Meta-analyses revealed high inconsistency (I2≥75%) and inefficacy of LPAI formulations against current field viruses, while potential sources of inconsistent VE were formulation of seed-homologous vaccines and the species vaccinated. We conclude that the VE of commercial vaccines in Indonesia changes as Indonesian HPAI/H5N1 evolve into new clades, which should warrant continuous matching between vaccine-seeds and emerging HPAI/H5N1. Furthermore, given the characteristics of the new Indonesian dominant HPAI/H5N1 clade, further studies to confirm VE across species are warranted. control group, and 7) it reported an outcome that allowed estimation of VE as defined in the 48 research question. When title and abstract were insufficient to judge relevance, articles were 49 retained for full text assessment. Hand-search of citations in the reference list of relevant articles 50 was performed to identify other relevant publications missed by the search strategy. 51 The inclusion criteria were developed a priori. Articles with English title and abstract but written 52 in a different language were retained and the corresponding author consulted for an English 53 version; if this was not available, the article was translated using Google Translate 54 (https://translate.google.com.au/), and the help of a native speaker. To be included, articles had to 55 report a randomized controlled trial, controlled trial, or challenge study as these study designs 56 allow assessment of VE [11] and report outcomes including seroprotective levels after 57 vaccination, viral shedding, or mortality after challenge with an Indonesian HPAI/H5N1. When 58 articles reported more than one trial or challenge study, only those that met the inclusion criteria 59 were included in the systematic review. A methodological quality assessment of articles was 60 performed using the risk of bias tool (RoB) [12] , following the approach recommended by heterogeneity were taken from a Mantel-Haenszel model as recommended for trials that report 89 few or zero clinical events [14] . Consistency was measured using I 2 as this is less affected by 90 power issues than heterogeneity tests [16] , a fundamental feature given the small size of efficacy 91 studies in poultry. Pooled RR, 95%CI, and VE were estimated using the metan routine [18] in 92 Stata v.12 [19] . 93 The methodological assessment focused solely on the systematic risk of bias that would affect 118 our evaluation of VE (Table S3 ). None of the publications reported random sequence generation.
RESULTS

94
Scope of the study and characteristics of publications included
119
In three publications [25, 29, 30] Group 3 gathers studies that performed prime-boosting of two and three doses on SPF, 164 commercial, or native chickens ( Fig.S1 ). Birds were vaccinated between 4 and 16 weeks of age, 165 challenged either 2 or 3wpv, and followed-up to assess survivorship between 7 and 14dpc. Group 4 includes studies that performed primary vaccination in 1 or 10-day-old chicks, with and 173 without maternally-derived antibodies (MDA) against AI viruses ( Fig.S2 ). These birds were 174 challenged 3 or 4wpv and followed-up for 10 or 14dpc (Table 1) . Among the chicks carrying 175 MDA against Legok03, those vaccinated at one day of age had increased risk of death, while 176 only those vaccinated at 10 days of age with Legok03 were protected against death after the 177 homologous challenge (v.4). In day-old chicks with and without MDA against H5N9, FPvect83 178 formulations prevented neither respiratory viral shedding 2dpc nor death 4wpv. 180 Meta-analyses were dominated by studies involving LPAI and reversed-genetics formulations.
Meta-analysis
181
Only formulations carrying Pwt06 were tested across species (Figures 3). I 2 is equal to 0% when 182 the pooled VE is consistent and variation is due to chance; values of 25%, 50%, and 75% 183 approximate low, moderate, and high heterogeneity, attributable to genuine differences of VE 184 being pooled.
185
Chickens that received a primary dose of LPAI formulations and challenged with a second order 186 clade virus (Indo03) were consistently protected around 50% for viral shedding and 90% for 
227
The OIE's protocols to assess VE against AI include the use of SPF birds, challenged at least 228 3wpv, using a standardized viral challenge dose able to kill at least 90% of the control group [1]. 229 We grouped the studies that most closely resembled the OIE's protocol (Group 1), and formed 230 three other groups that varied such protocol. We found that seroprotective levels induced by Indonesia to the use of homologous H5N1 vaccines only [50] . 286 The pooled VE of Pwt06 vaccines against the duck-origin Suko12, showed that extra-label use of 287 vaccines may affect VE consistency. The subgroup meta-analysis showed that VE consistency Indonesia [50] . The meta-analyses performed showed that VE consistency is affected by the n/a n/a n/a n/a n/a n/a n/a 20 20 20 20 20 n/a n/a n/a n/a n/a n/a n/a Tables   Table 3. Subgroup meta-analysis. Pooled vaccine efficacy (VE), 95% confidence interval (95%CI) and I 2 test against respiratory and cloacal viral shedding 2-day post challenge (dpc) and mortality at the end of the follow-up period, grouped by type of chicken, species, vaccine seed, and clade of challenge¹ Figure 2 . Group 1. Geometric mean titres estimated through hemagglutinin inhibition test against the vaccine-homologous antigen (GMT H) and challenge virus (GMT Ch); risk ratios, vaccine efficacy (1risk ratio), and corresponding 95% confidence interval against respiratory viral shedding 2-day post challenge (dpc) and death at the end of follow-up period. Asterisks denote GMT not estimated; n/a denote outcome not reported in the original article. Figure 3 . Group 2. Geometric mean titers estimated through hemagglutinin inhibition test against the vaccine-homologous antigen (GMT H) and challenge virus (GMT Ch); risk ratios, vaccine efficacy (1risk ratio), and corresponding 95% confidence interval against respiratory viral shedding 2-day post challenge (dpc) and death at the end of follow-up period. Asterisks denote GMT not estimated; n/a denote outcome not reported in the original article. Figure S1 . Group 3. Geometric mean titres estimated through hemagglutinin inhibition test against the vaccine-homologous antigen (GMT H) and challenge virus (GMT Ch); risk ratios, vaccine efficacy (1-risk ratio), and corresponding 95% confidence interval against respiratory viral shedding 2-day post challenge (dpc) and death at the end of follow-up period. Asterisks denote GMT not estimated; n/a denote outcome not reported in the original article. Figure S2 . Group 4. Geometric mean titres estimated through hemagglutinin inhibition test against the vaccine-homologous antigen (GMT H) and challenge virus (GMT Ch); risk ratios, vaccine efficacy (1-risk ratio), and corresponding 95% confidence interval against respiratory viral shedding 2-day post challenge (dpc) and death at the end of follow-up period. Asterisks denote GMT not estimated; n/a denote outcome not reported in the original article. 
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